|сгенерировать QR код
Открытый доступ
Только для подписчиков
Биомаркеры раннего выявления поражения сердца и сосудов у детей с хронической болезнью почек
https://doi.org/10.36485/1561-6274-2025-29-2-17-26
EDN: IAFPLT
Аннотация
В статье представлен обзор современных представлений о факторах риска хронической болезни почек (ХБП) и сердечно-сосудистых заболеваний в педиатрической популяции. Рассмотрены группы основных структурных и функциональных маркеров у детей с артериальной гипертензией и при ХБП у детей. Приведены результаты исследований, подтверждающих их ценность в отношении скрининга, диагностики и оценки сердечно-сосудистого прогноза. Обсуждены различия в подходах к использованию биомаркеров у взрослых и детей.
Ключевые слова
Об авторах
И. А. Каримджанов
Ташкентская медицинская академия
Узбекистан
Узбекистан
Проф. Каримджанов Илхамджан Асамович - д-р мед. наук Ташкентская медицинская академия, кафедра детских болезней №2.
100102, Ташкент, ул. Фароби, д. 2. Тел. (+998) 903515346
Г. Х. Исканова
Ташкентская медицинская академия
Узбекистан
Узбекистан
Доц. Исканова Гулшан Холдоровна - канд. мед. наук. Ташкентская медицинская академия, кафедра детских болезней №2.
100102, Ташкент, ул. Фароби, д. 2. Тел. (+998) 903706440
М. Ш. Мадаминова
Ташкентская медицинская академия
Узбекистан
Узбекистан
Ассистент Мадаминова Малика Шавкатовна - PhD. Ташкентская медицинская академия, кафедра детских болезней №2.
100102, Ташкент, ул. Фароби, д. 2., Тел. (+998) 90 1757180
А. С. Газиева
Ташкентская медицинская академия
Узбекистан
Узбекистан
Ассистент Газиева Азиза Сафаровна - Ташкентская медицинская академия, кафедра детских болезней №2.
100102, Ташкент, ул. Фароби, д. 2, Тел. (+998) 90 9612294
М. К. Тогаев
Ташкентская медицинская академия
Узбекистан
Узбекистан
Ассистент Тогаев Мухиддин Курбонмуродович - Ташкентская медицинская академия, кафедра детских болезней №2.
100102, Ташкент, ул. Фароби, д. 2, Тел. (+998) 99 0157555
Список литературы
1. Савенкова НД. Нефрогенная артериальная гипертензия у детей и подростков: причины, классифифкация, диагностика. Российский вестник перинатологии и педиатрии 2017;62(4):43–48. doi: 10.21508/1027-4065-2017-62-4-43-48
2. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: A systematic analysis forthe Global Burden of Disease Study 2017. Lancet 2018, 392, 1923–1994. doi: 10.1016/S0140-6736(18)32225-6
3. Baker-Smith CM, Flinn SK, Flynn JT, Kaelber DC, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B et al. Diagnosis, Evaluation, and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2018, 142, e20182096. doi: 10.1542/peds.2018–2096
4. Song P, Zhang Y, Yu J, Zha M, Zhu Y, Rahimi K, Rudan I. Global Prevalence of Hypertension in Children: A Systematic Review and Meta-analysis. JAMA Pediatr 2019, 173, 1154–1163. doi:10.1001/jamapediatrics.2019.3310
5. Каримджанов ИА, Исканова ГХ, Исраилова НА. Артериальная гипертензия у детей с нефротическим синдромом. Нефрология 2021;25(3):20–27. doi: 10.36485/1561-6274-202125-3-20-27
6. Robinson CH, Chanchlani R. High Blood Pressure in Children and Adolescents: Current Perspectives and Strategies to Improve Future Kidney and Cardiovascular Health. Kidney Int Rep 2022;7: 954–970. doi: 10.1016/j.ekir.2022.02.018
7. Kaelber DC, Liu W, Ross M, Localio AR, Leon JB, Pace WD, Wasserman RC, Fiks AG. Comparative Effectiveness Research Through Collaborative Electronic Reporting (CER2) Consortium. Diagnosis and Medication Treatment of Pediatric Hypertension: A Retrospective Cohort Study. Pediatrics 2016;138:e20162195. doi: 10.1542/peds.2016-2195
8. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168–175. doi: 10.1161/01.atv.0000051384.43104.fc
9. De Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, Mietus-Snyder M, Mitsnefes MM, Peterson AL, St-Pierre J et al. Cardiovascular risk reduction in high-risk pediatric patients: A scientific statement from the American Heart Association. Circulation 2019;139:e603–e634. doi:10.1161/CIR.0000000000000618
10. Surma S, Czober T, Lepich T, Sierka O, Bajor G. Selected biomarkers of atherosclerosis—Clinical aspects. Acta Angiol 2020;26:28–39. doi: 10.5603/AA.2020.0005
11. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140:e20171904. doi: 10.1542/peds.2017-1904
12. Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, Invitti C, Litwin M, Mancia G, Pall D et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016;34:1887–1920. doi: 10.1097/HJH.0000000000001039
13. Dionne JM, Harris KC, Benoit G, Feber J, Poirier L, Cloutier L, Nakhla M, Rabi DM, Daskalopoulou SS, Fournier A et al. Hypertension Canada’s 2017 Guidelines for the Diagnosis, Assessment, Prevention, and Treatment of Pediatric Hypertension. Can J Cardiol 2017;33:577–585. doi: 10.1016/j.cjca.2017.03.007
14. Sharma AK, Metzger DL, Rodd CJ. Prevalence and severity of high blood pressure among children based on the 2017American Academy of Pediatrics guidelines. JAMA Pediatr 2018;172: 557–565. doi: 10.1001/jamapediatrics.2018.0223
15. Duncombe SL, Voss C, Harris KC. Oscillometric and auscultatory blood pressure measurement methods in children: A systematic review and meta-analysis. J Hypertens 2017;35: 213–224. doi: 10.1097/HJH.0000000000001178
16. Flynn JT, Mitsnefes M, Pierce C, Cole SR, Parekh RS, Furth SL, Warady BA. Chronic Kidney Disease in Children Study Group. Blood pressure in children with chronic kidney disease: A report from the Chronic Kidney Disease in Children study.Hypertension 2008;52:631–637. doi: 10.1161/HYPERTENSIONAHA.108.110635
17. Samuels J, Ng D, Flynn JT, Mitsnefes M, Poffenbarger T, Warady BA, Furth S. Chronic Kidney Disease in Children Study Group. Ambulatory blood pressure patterns in children with chronic kidney disease. Hypertension 2012;60:43–50. doi: 10.1161/HYPERTENSIONAHA.111.189266
18. Schaefer F, Doyon A, Azukaitis K, Bayazit A, Canpolat N, Duzova A, Niemirska A, Sözeri B, Thurn D, Anarat A et al. Cardiovascular Phenotypes in Children with CKD: The 4C Study. Clin J Am Soc Nephrol 2017;12:19–28. doi: 10.2215/CJN.01090216
19. Kupferman JC, Aronson Friedman L, Cox C, Flynn J, Furth S, Warady B, Mitsnefes M, CKiD Study Group. BP control and left ventricular hypertrophy regression in children with CKD. J Am Soc Nephrol 2014;25:167–174. doi: 10.3390/jcm9020336
20. Weaver DJ, Mitsnefes M. Cardiovascular Disease in Children and Adolescents with Chronic Kidney Disease. Semin Nephrol 2018;38:559–569. doi: 10.1016/j.semnephrol.2018.08.002
21. Falkner B, Lurbe E. Primordial prevention of high blood pressure in childhood: An opportunity not to be missed. Hypertension 2020;75:1142–1150. doi: 10.1161/HYPERTENSIONAHA.119.14059
22. Major RW, Cheng MRI, Grant RA, Shantikumar S, Xu G, Oozeerally I, Brunskill NJ, Gray LJ. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and metaanalysis. PLoS ONE 2018;13:e0192895. doi: 10.1371/journal. pone.0192895
23. Савенкова НД, Григорьева ОП. Прогноз сердечнососудистых осложнений и прогрессирования почечной недостаточности у педиатрических пациентов с хронической болезнью почек в соответствии с классификациями NKF-K/ DOQI (2002) и KDIGO (2012). Рос вестн перинатол и педиатр 2022; 67(2):12–19. doi: 10,21508/1027–4065–2022–67–2–12–19
24. Савенкова НД, Григорьева ОП. Педиатрические проблемы стратификации тяжести стадий, сердечно-сосудистых осложнений и почечного прогноза хронической болезни почек по классификациям NKF-K/DOQI (2002) И KDIGO (2012). Нефрология 2021;25(3):9–19. doi: 10.36485/1561-6274-202125-3-9-19
25. Каримджанов ИА, Юсупова ГА, Исканова ГХ, Исраилова НА. Артериальная гипертензии как фактор риска развития хронической болезни почек у детей с врожденными аномалиями почек и мочевыводящих путей ВАПМП/ CAKUT и ее коррекция. Нефрология 2024;28(1):43–49. doi:10.36485/15616274-2024-28-1-43-49
26. Shroff R, Dégi A, Kerti A, Kis E, Cseprekál O, Tory K, Szabó AJ, Reusz GS. Cardiovascular risk assessment in children with chronic kidney disease. Pediatr Nephrol 2013;28:875–884. doi: 10.1007/s00467-012-2325-3
27. Vidi SR. Role of hypertension in progression of chronic kidney disease in children. Curr Opin Pediatr 2018;30:247–251. doi: 10.1097/MOP.0000000000000595
28. Guzman-Limon ML, Jiang S, Ng D, Flynn JT, Warady B, Furth SL, Samuels JA, Chronic Kidney Disease in Children study. Nocturnal Hypertension in ChildrenWith Chronic Kidney Disease Is Common and AssociatedWith Progression to Kidney Replacement Therapy. Hypertension 2022;79:2288–2297. doi: 10.1161/HYPERTENSIONAHA.121.18101
29. Düzova A, Karabay Bayazit A, Canpolat N, Niemirska A, Kaplan Bulut I, Azukaitis K, Karagoz T, Oguz B, Erdem S, Anarat A et al. Isolated nocturnal and isolated daytime hypertension associate with altered cardiovascular morphology and function in children with chronic kidney disease: Findings from the Cardiovascular Comorbidity in Children with Chronic Kidney Disease study. J Hypertens 2019;37:2247–2255. doi: 10.1097/HJH.0000000000002160
30. Halbach S. Practical application of ABPM in the pediatric nephrology clinic. Pediatr Nephrol 2020;35:2067–2076. doi: 10.1007/s00467-019-04361-0
31. Brady TM, Schneider MF, Flynn JT, Cox C, Samuels J, Saland J, White CT, Furth S, Warady BA, Mitsnefes M. Carotid intima-media thickness in children with CKD: Results from the CKiD study. Clin J Am Soc Nephrol 2012;7:1930–1937. doi: 10.2215/CJN.03130312
32. Day TG, Park M, Kinra S. The association between blood pressure and carotid intima-media thickness in children: A systematic review. Cardiol Young 2017;27:1295–1305. doi: 10.1017/S1047951117000105
33. Hanssen H. Vascular biomarkers in the prevention of childhood cardiovascular risk: From concept to clinical implementation. Front Cardiovasc Med 2022;9:935810. doi.org/10.3389/fcvm.2022.935810
34. Khandelwal P, Murugan V, Hari S, Lakshmy R, Sinha A, Hari P, Bagga A. Dyslipidemia, carotid intima-media thickness and endothelial dysfunction in children with chronic kidney disease. Pediatr Nephrol 2016;31:1313–1320. doi: 10.1007/s00467-0163350-4
35. Hsu CN, Lu PC, Lo MH, Lin IC, Tain YL. The Association between Nitric Oxide Pathway, Blood Pressure Abnormalities, and Cardiovascular Risk Profile in Pediatric Chronic Kidney Disease. Int J Mol Sci 2019;20:5301. doi: 10.3390/ijms20215301
36. Boutouyrie P, Chowienczyk P, Humphrey JD, Mitchell GF. Arterial Stiffness and Cardiovascular Risk in Hypertension. Circ Res 2021;128:864–886. doi: 10.1161/CIRCRESAHA.121.318061
37. Azukaitis K, Jankauskiene A, Schaefer F, Shroff R. Pathophysiology and consequences of arterial stiffness in children with chronic kidney disease. Pediatr Nephrol 2021;36:1683–1695. doi: 10.1007/s00467-020-04732-y
38. Tasdemir M, Eroglu AG, Canpolat N, Konukoglu D, Agba¸s A, Sevim MD, Çalı¸skan S, Sever L. Cardiovascular alterations do exist in children with stage-2 chronic kidney disease. Clin Exp Nephrol 2016;20:926–933. doi: 10.1007/s10157-016-1234-3
39. Conkar S, Mir S, Dogan E, Ülger Tutar Z. Association of Vitamin D Deficiency with Increased Pulse Wave Velocity and Augmentation Index in Children With Chronic Kidney Disease. Iran J Kidney Dis 2018;12:275–280. PMID: 30367018
40. Alves C, Pinho JF, Dos Santos LM, Magalhães G, da Silva JM, Fontes FL, Caligiorne SM, Pinheiro S, Rodrigues-Machado MG. Augmentation index, a predictor of cardiovascular events, is increased in children and adolescents with primary nephrotic syndrome. Pediatr Nephrol 2020;35:815–827. doi: 10.1007/s00467-019-04434-0
41. Raina R, Polaconda S, Nair N, Chakraborty R, Sethi S, Krishnappa V, Kapur G, Mhanna M, Kusumi K. Association of pulse pressure, pulse pressure index, and ambulatory arterial stiffness index with kidney function in a cross-sectional pediatric chronic kidney disease cohort from the CKiD study. J Clin Hypertens 2020; 22:1059–1069. doi: 10.1111/jch.13905
42. de Simone G, Mancusi C, Hanssen H, Genovesi S, Lurbe E, Parati G, Sendzikaite S, Valerio G, Di Bonito P, Di Salvo G et al. Hypertension in children and adolescents. Eur Heart J 2022;43: 3290–3301. doi: 10.1093/eurheartj/ehac328
43. Zhang WR, Parikh CR. Biomarkers of Acute and Chronic Kidney Disease. Annu Rev Physiol 2019;81:309–333. doi: 10.1146/annurev-physiol-020518-114605
44. Lousa I, Reis F, Beirão I, Alves R, Belo L, Santos-Silva A. New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature. Int J Mol Sci 2020;22:43. doi: 10.3390/ijms22010043
45. Greenberg JH, Kakajiwala A, Parikh CR, Furth S. Emerging biomarkers of chronic kidney disease in children. Pediatr Nephrol 2018;33:925–933. doi: 10.1007/s00467-017-3701-9. doi: 10.1007/s00467-017-3701-9
46. Sandokji I, Greenberg JH. Plasma and Urine Biomarkers of CKD: A Review of Findings in the CKiD Study. Semin Nephrol 2021; 41:416–426. doi: 10.1016/j.semnephrol.2021.09.003
47. Carlström M. Nitric oxide signalling in kidney regulation and cardiometabolic health. Nat Rev Nephrol 2021;17:575–590. doi: 10.1038/s41581-021-00429-z
48. McWilliam SJ, Wright RD, Welsh GI, Tuffin J, Budge KL, Swan L, Wilm T, Martinas IR, Littlewood J, Oni L. The complex interplay between kidney injury and inflammation. Clin Kidney J 2020;14:780–788. doi: 10.1093/ckj/sfaa164
49. Stopic B, Medic-Brkic B, Savic-Vujovic K, Davidovic Z, Todorovic J, Dimkovic N. Biomarkers and Predictors of Adverse Cardiovascular Events in Different Stages of Chronic Kidney Disease. Dose Response 2022;20:15593258221127568. doi: 10.1177/15593258221127568
50. Moreira JM, da Silva AN, Marciano Vieira ÉL, Teixeira AL, Kummer AM, Simões E, Silva AC. Soluble tumor necrosis factor receptors are associated with severity of kidney dysfunction in pediatric chronic kidney disease. Pediatr Nephrol 2019; 34:349–352. doi: 10.1007/s00467-018-4124-y
51. Holle J, Bartolomaeus H, Löber U, Behrens F, Bartolomaeus TUP, Anandakumar H, Wimmer MI, Vu DL, Kuhring M, Brüning U et al. Inflammation in Children with CKD Linked to Gut Dysbiosis and Metabolite Imbalance. J Am Soc Nephrol 2022;13: doi: 10.1681/ASN.2022030378
52. Hsu CN, Tain YL. Developmental Origins of Kidney Disease: Why Oxidative Stress Matters? Antioxidants 2020;10:33. doi: 10.3390/antiox10010033
53. Droz˙dz˙ D, Kwinta P, Sztefko K, Kordon Z, Droz˙dz˙ T, Ła˛tka M, Miklaszewska M, Zachwieja K, Rudzin´ ski A, Pietrzyk JA. Oxidative Stress Biomarkers and Left Ventricular Hypertrophy in Children with Chronic Kidney Disease. Oxidative Med Cell Longev 2016;7520231. doi: 10.1155/2016/7520231
54. Rossaint J, Unruh M, Zarbock A. Fibroblast growth factor 23 actions in inflammation: A key factor in CKD outcomes. Nephrol Dial Transplant 2017;32:1448–1453. [CrossRef]
55. Hu PP, Bao JF, Li A. Roles for fibroblast growth factor-23 and -Klotho in acute kidney injury. Metabolism 2021;116:154435. doi: 10.1093/ndt/gfw331
56. Grund A, Sinha MD, Haffner D, Leifheit-Nestler M. Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease—A Pediatric Perspective. Front Pediatr 2021;9: 702719. doi: 10.3389/fped.2021.702719
57. Sinha MD, Turner C, Booth CJ, Waller S, Rasmussen P, Goldsmith DJ, Simpson JM. Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease. Pediatr Nephrol 2015;30:1843–1852. doi: 10.1007/s00467-015-3125-3
58. Zhou LT, Qiu S, Lv LL, Li ZL, Liu H, Tang RN, Ma KL, Liu BC. Integrative Bioinformatics Analysis Provides Insight into the Molecular Mechanisms of Chronic Kidney Disease. Kidney Blood Press Res 2018;43:568–581. doi: 10.1159/000488830
59. Chebotareva N, Vinogradov A, McDonnell V, Zakharova NV, Indeykina MI, Moiseev S, Nikolaev EN, Kononikhin AS.Urinary Protein and Peptide Markers in Chronic Kidney Disease. Int J Mol Sci 2021;22:2123. doi: 10.3390/ijms222212123
60. Cummins TD, Korte EA, Bhayana S, Merchant ML, Barati MT, Smoyer WE, Klein JB. Advances in proteomic profiling of pediatric kidney diseases. Pediatr Nephrol 2022;37:2255–2265. doi: 10.1007/s00467-022-05497-2
61. Chen WL, Tain YL, Chen HE, Hsu CN. Cardiovascular Disease Risk in ChildrenWith Chronic Kidney Disease: Impact of Apolipoprotein C-II and Apolipoprotein C-III. Front Pediatr 2021; 9:706323. doi: 10.1016/j.kint.2020.05.030
62. Liao WT, Chen WL, Tain YL, Hsu CN. Complement Factor H and Related Proteins as Markers of Cardiovascular Risk in Pediatric Chronic Kidney Disease. Biomedicines 2022;10:1396. doi: 10.3390/biomedicines10061396
63. Brooks ER, Lin DC, Langman CB, Thompson JW, JohnWilliams LS, Furth SL, Warady B, Haymond S. Metabolomic Patterns in Adolescents with Mild to Moderate CKD. Kidney Int Rep 2019;4:720–723. doi: 10.1038/nrneph.2017.30
64. Benito S, Sánchez-Ortega A, Unceta N, Andrade F, Aldámiz-Echevarria L, Goicolea MA, Barrio RJ. Untargeted metabolomics for plasma biomarker discovery for early chronic kidney disease diagnosis in pediatric patients using LC-QTOFMS. Analyst 2018;143:4448–4458. doi: 10.1039/c8an00864g
65. Denburg MR, Xu Y, Abraham AG, Coresh J, Chen J, Grams ME, Feldman HI, Kimmel PL, Rebholz CM, Rhee EP et al. Metabolite Biomarkers of CKD Progression in Children. Clin J Am Soc Nephrol 2021;16:1178–1189. doi: 10.2215/CJN.00220121
66. Schultheiss UT, Sekula P. The Promise of Metabolomics in Decelerating CKD Progression in Children. Clin J Am Soc Nephrol 2021;16:1152–1154. doi: 10.2215/CJN.07400521
67. Sood MM, Murphy MS, Hawken S, Wong CA, Potter BK, Burns KD, Tsampalieros A, Atkinson KM, Chakraborty P, Wilson K. Association Between Newborn Metabolic Profiles and Pediatric Kidney Disease. Kidney Int Rep 2018;3:691–700. doi: 10.1016/j.ekir.2018.02.001
68. Riccio S, Valentino MS, Passaro AP, Izzo M, Guarino S, Miraglia Del Giudice E, Marzuillo P, Di Sessa A. New Insights from Metabolomics in Pediatric Renal Diseases. Children 2022;9:118. doi: 10.3390/children9010118
69. Holle J, Querfeld U, Kirchner M, Anninos A, Okun J, Thurn-Valsassina D, Bayazit A, Niemirska A, Canpolat N, Bulut IK et al. Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease. Pediatr Nephrol 2019;34: 2571–2582. doi: 10.1007/s00467-019-04331-6
70. Mitsnefes MM. Cardiovascular Disease Risk Factors in Chronic Kidney Disease in Children. Semin Nephrol 2021;41: 434–438. doi: 10.1016/j.semnephrol.2021.09.005
71. Moˇcnik M, Marˇcun Varda N. Current Knowledge of Selected Cardiovascular Biomarkers in Pediatrics: Kidney Injury Molecule-1,Salusin-, Uromodulin, and Adropin. Children 2022;9: 102. doi: 10.3390/children9010102
72. Lee AM, Hu J, Xu Y, Abraham AG, Xiao R, Coresh J, Rebholz C, Chen J, Rhee EP, Feldman HI et al. Using Machine Learning to Identify Metabolomic Signatures of Pediatric Chronic Kidney Disease Etiology. J Am Soc Nephrol 2022;33:375–386. doi: 10.1681/ASN.2021040538
Рецензия
Для цитирования:
Каримджанов И.А., Исканова Г.Х., Мадаминова М.Ш., Газиева А.С., Тогаев М.К. Биомаркеры раннего выявления поражения сердца и сосудов у детей с хронической болезнью почек. Нефрология. 2025;29(2):17-26. https://doi.org/10.36485/1561-6274-2025-29-2-17-26. EDN: IAFPLT
For citation:
Karimdzhanov I.A., Iskanova G.Kh., Madaminova M.Sh., Gazieva A.S., Togaev M.K. Biomarkers of early detection of heart and vascular damage in children with chronic kidney disease. Nephrology (Saint-Petersburg). 2025;29(2):17-26. (In Russ.) https://doi.org/10.36485/1561-6274-2025-29-2-17-26. EDN: IAFPLT
Просмотров:
13
Послать статью по эл. почте 